Enos Bernasconi
Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes
Fenner L, Egger M, Helbling P, Böttger E, Bodmer T, Schrenzel J, Bernasconi E, Hoffmann M, Cavassini M, Fehr J, Janssens J, Gagneux S, Swiss HIV Cohort and Molecular Epidemiology of Tuberculosis Study Groups. Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes. PloS one 2012; 7:e34186.
30.03.2012Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes
30.03.2012PloS one 2012; 7:e34186
Fenner Lukas, Egger Matthias, Helbling Peter, Böttger Erik C, Bodmer Thomas, Schrenzel Jacques, Bernasconi Enos, Hoffmann Matthias, Cavassini Matthias, Fehr Jan, Janssens Jean-Paul, Gagneux Sebastien, Swiss HIV Cohort and Molecular Epidemiology of Tuberculosis Study Groups
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir
Young J, Bucher H, Battegay M, Weber R, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Furrer H, Fux C, Schäfer J, the Swiss HIV Cohort Study. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. AIDS 2012; 26:567-575.
13.03.2012Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir
13.03.2012AIDS 2012; 26:567-575
Young Jim, Bucher Heiner C, Battegay Manuel, Weber Rainer, Cavassini Matthias, Calmy Alexandra, Vernazza Pietro, Bernasconi Enos, Furrer Hansjakob, Fux Christoph A, Schäfer Juliane, the Swiss HIV Cohort Study
Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo
Pillai S, Wong J, Günthard H, Ledergerber B, Bernasconi E, Bregenzer A, Hirschel B, Battegay M, Fellay J, Rauch A, Kovari H, Greene W, Yukl S, Fujimoto K, Monto A, Skasko M, Guatelli J, Abdel-Mohsen M, Swiss HIV Cohort Study. Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. Proc Natl Acad Sci USA 2012; 109:3035-40.
06.02.2012Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo
06.02.2012Proc Natl Acad Sci USA 2012; 109:3035-40
Pillai Satish K, Wong Joseph K, Günthard Huldrych F, Ledergerber Bruno, Bernasconi Enos, Bregenzer Andrea, Hirschel Bernard, Battegay Manuel, Fellay Jacques, Rauch Andri, Kovari Helen, Greene Warner C, Yukl Steven, Fujimoto Katsuya, Monto Alexander, Skasko Mark, Guatelli John, Abdel-Mohsen Mohamed, Swiss HIV Cohort Study
Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy
Glass T, Marzolini C, Battegay M, Wandeler G, Bernasconi E, Hirschel B, Nicca D, Rickenbach M, Günthard H, Bucher H, Csajka C, Decosterd L, Telenti A, Rotger M, the Swiss HIV Cohort Study. Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy. PloS one 2012; 7:e29186.
03.01.2012Determinants of Sustained Viral Suppression in HIV-Infected Patients with Self-Reported Poor Adherence to Antiretroviral Therapy
03.01.2012PloS one 2012; 7:e29186
Glass Tracy R, Marzolini Catia, Battegay Manuel, Wandeler Gilles, Bernasconi Enos, Hirschel Bernard, Nicca Dunja, Rickenbach Martin, Günthard Huldrych F, Bucher Heiner C, Csajka Chantal, Decosterd Laurent, Telenti Amalio, Rotger Margalida, the Swiss HIV Cohort Study
Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study
Staehelin C, Furrer H, Bernasconi E, Schmid P, Cavassini M, Elzi L, Weber R, Calmy A, Keiser O, Swiss HIV Cohort Study. Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2012; 59:79-85.
01.01.2012Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study
01.01.2012J Acquir Immune Defic Syndr 2012; 59:79-85
Staehelin Cornelia, Furrer Hansjakob, Bernasconi Enos, Schmid Patrick, Cavassini Matthias, Elzi Luigia, Weber Rainer, Calmy Alexandra, Keiser Olivia, Swiss HIV Cohort Study
A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA
Wandeler G, Furrer H, Vernazza P, Clerc O, Battegay M, Bernasconi E, Günthard H, Hirschel B, Keiser O, Swiss HIV Cohort Study. A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA. PloS one 2011; 6:e27903.
20.12.2011A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA
20.12.2011PloS one 2011; 6:e27903
Wandeler Gilles, Furrer Hansjakob, Vernazza Pietro, Clerc Olivier, Battegay Manuel, Bernasconi Enos, Günthard Huldrych F, Hirschel Bernard, Keiser Olivia, Swiss HIV Cohort Study
Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic
Boillat Blanco N, Cavassini M, Bertisch B, Weber R, Rauch A, Elzi L, Calmy A, Bernasconi E, Giulieri S, Da Costa V, Probst A, Bochud P. Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic. J Acquir Immune Defic Syndr 2011; 58:472-4.
15.12.2011Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic
15.12.2011J Acquir Immune Defic Syndr 2011; 58:472-4
Boillat Blanco Noémie, Cavassini Matthias, Bertisch Barbara, Weber Rainer, Rauch Andri, Elzi Luigia, Calmy Alexandra, Bernasconi Enos, Giulieri Stefano, Da Costa Vreneli Waelti, Probst Arnold, Bochud Pierre-Yves
Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption
von Wyl V, Günthard H, Joos B, Weber R, Vernazza P, Hirschel B, Rauch A, Cavassini M, Bernasconi E, Battegay M, Kuster H, Niederoest B, Fischer M, Gianella S, the Swiss HIV Cohort Study (SHCS). Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. PloS one 2011; 6:e27463.
15.11.2011Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption
15.11.2011PloS one 2011; 6:e27463
von Wyl Viktor, Günthard Huldrych F, Joos Beda, Weber Rainer, Vernazza Pietro, Hirschel Bernard, Rauch Andri, Cavassini Matthias, Bernasconi Enos, Battegay Manuel, Kuster Herbert, Niederoest Barbara, Fischer Marek, Gianella Sara, the Swiss HIV Cohort Study (SHCS)
Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection
Elzi L, Bassetti S, Bernasconi E, Hoffmann M, Hirschel B, Cavassini M, Fehr J, Furrer H, Steffen I, Battegay M. Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection. BMC Infect Dis 2011; 11:319.
15.11.2011Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection
15.11.2011BMC Infect Dis 2011; 11:319
Elzi Luigia, Bassetti Stefano, Bernasconi Enos, Hoffmann Matthias, Hirschel Bernard, Cavassini Matthias, Fehr Jan, Furrer Hansjakob, Steffen Ingrid, Battegay Manuel
Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations
von Wyl V, Günthard H, Ledergerber B, Vernazza P, Hirschel B, Furrer H, Cavassini M, Bernasconi E, Battegay M, Klimkait T, Cellerai C, Shah C, Böni J, Yerly S, Swiss HIV Cohort Study. Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin Infect Dis 2011; 54:131-40.
04.11.2011Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations
04.11.2011Clin Infect Dis 2011; 54:131-40
von Wyl Viktor, Günthard Huldrych F, Ledergerber Bruno, Vernazza Pietro, Hirschel Bernard, Furrer Hansjakob, Cavassini Matthias, Bernasconi Enos, Battegay Manuel, Klimkait Thomas, Cellerai Cristina, Shah Cyril, Böni Jürg, Yerly Sabine, Swiss HIV Cohort Study
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B
Scherrer A, Günthard H, Held L, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Hirschel B, Rauch A, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis 2011; 53:1143-52.
13.10.2011Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B
13.10.2011Clin Infect Dis 2011; 53:1143-52
Scherrer Alexandra U, Günthard Huldrych F, Held Leonhard, Bernasconi Enos, Vernazza Pietro, Elzi Luigia, Cavassini Matthias, Hirschel Bernard, Rauch Andri, Bürgisser Philippe, Klimkait Thomas, Yerly Sabine, Böni Jürg, von Wyl Viktor, Ledergerber Bruno, Swiss HIV Cohort Study
Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study
Hasse B, Weber R, Bernasconi E, Bertisch B, Cavassini M, Hirschel B, Battegay M, Furrer H, Ledergerber B, Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53:1130-9.
13.10.2011Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study
13.10.2011Clin Infect Dis 2011; 53:1130-9
Hasse Barbara, Weber Rainer, Bernasconi Enos, Bertisch Barbara, Cavassini Matthias, Hirschel Bernhard, Battegay Manuel, Furrer Hansjakob, Ledergerber Bruno, Swiss HIV Cohort Study
The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland
von Wyl V, Günthard H, Bonhoeffer S, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Staehelin C, Cavassini M, Hirschel B, Weber R, Klimkait T, Bürgisser P, Shah C, Böni J, Yerly S, Kouyos R, Swiss HIV Cohort Study. The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland. J Infect Dis 2011; 204:1095-103.
01.10.2011The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland
01.10.2011J Infect Dis 2011; 204:1095-103
von Wyl Viktor, Günthard Huldrych F, Bonhoeffer Sebastian, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Battegay Manuel, Staehelin Cornelia, Cavassini Matthias, Hirschel Bernard, Weber Rainer, Klimkait Thomas, Bürgisser Philippe, Shah Cyril, Böni Jürg, Yerly Sabine, Kouyos Roger D, Swiss HIV Cohort Study
A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)
Nguyen A, Schmid P, Bernasconi E, Rauch A, Elzi L, Mello A, Cavassini M, Mercier I, Delhumeau C, Calmy A, Hirschel B. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS 2011; 25:1481-7.
31.07.2011A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study)
31.07.2011AIDS 2011; 25:1481-7
Nguyen Alain, Schmid Patrick, Bernasconi Enos, Rauch Andri, Elzi Luigia, Mello Aurelie F, Cavassini Matthias, Mercier Isabelle, Delhumeau Cécile, Calmy Alexandra, Hirschel Bernard
Ageing with HIV: medication use and risk for potential drug-drug interactions
Marzolini C, Elzi L, Battegay M, Khoo S, Bernasconi E, Vernazza P, Calmy A, Cavassini M, Furrer H, Weber R, Back D, Swiss HIV Cohort Study Members. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66:2107-11.
16.06.2011Ageing with HIV: medication use and risk for potential drug-drug interactions
16.06.2011J Antimicrob Chemother 2011; 66:2107-11
Marzolini Catia, Elzi Luigia, Battegay Manuel, Khoo Saye, Bernasconi Enos, Vernazza Pietro, Calmy Alexandra, Cavassini Matthias, Furrer Hansjakob, Weber Rainer, Back David, Swiss HIV Cohort Study Members
Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque
Rotger M, Miró J, Palou E, Hoffmann M, Massanella M, Blanco J, Woods M, Günthard H, de Bakker P, Douek D, Silvestri G, Martinez-Picado J, Hirschel B, Fellay J, Erkizia I, Dalmau J, Rauch A, McLaren P, Bosinger S, Martinez R, Sandler N, Roque A, Liebner J, Battegay M, Bernasconi E, Descombes P, Telenti A. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest 2011; 121:2391-400.
09.05.2011Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque
09.05.2011J Clin Invest 2011; 121:2391-400
Rotger Margalida, Miró Jose M, Palou Eduard, Hoffmann Matthias, Massanella Marta, Blanco Julià, Woods Matthew, Günthard Huldrych F, de Bakker Paul, Douek Daniel C, Silvestri Guido, Martinez-Picado Javier, Hirschel Bernard, Fellay Jacques, Erkizia Itziar, Dalmau Judith, Rauch Andri, McLaren Paul, Bosinger Steven E, Martinez Raquel, Sandler Netanya G, Roque Annelys, Liebner Julia, Battegay Manuel, Bernasconi Enos, Descombes Patrick, Telenti Amalio
Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors
Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Hirschel B, Garzoni C, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Swiss HIV Cohort Study (SHCS). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2011; 57:24-31.
01.05.2011Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors
01.05.2011J Acquir Immune Defic Syndr 2011; 57:24-31
Scherrer Alexandra U, Günthard Huldrych F, Ledergerber Bruno, Bernasconi Enos, Vernazza Pietro, Battegay Manuel, Cavassini Matthias, Hirschel Bernard, Garzoni Christian, Bürgisser Philippe, Klimkait Thomas, Yerly Sabine, Böni Jürg, von Wyl Viktor, Swiss HIV Cohort Study (SHCS)
Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance
di Iulio J, Rauch A, Telenti A, Klenerman P, Barnes E, Hirschel B, Schmid P, Bernasconi E, Battegay M, Günthard H, Furrer H, Pulit S, Martinez R, Fellay J, Rotger M, Kelleher D, Fitzmaurice K, Ciuffi A, Swiss HIV Cohort Study. Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance. Hepatology 2011; 53:1446-54.
01.05.2011Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance
01.05.2011Hepatology 2011; 53:1446-54
di Iulio Julia, Rauch Andri, Telenti Amalio, Klenerman Paul, Barnes Eleanor, Hirschel Bernard, Schmid Patrick, Bernasconi Enos, Battegay Manuel, Günthard Huldrych F, Furrer Hansjakob, Pulit Sara, Martinez Raquel, Fellay Jacques, Rotger Margalida, Kelleher Dermot, Fitzmaurice Karen, Ciuffi Angela, Swiss HIV Cohort Study
Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death
Kaufmann G, Battegay M, Hirschel B, Bernasconi E, Vernazza P, Giulieri S, Furrer H, Weber R, Elzi L, Swiss HIV Cohort Study. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS 2011; 25:441-51.
20.02.2011Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death
20.02.2011AIDS 2011; 25:441-51
Kaufmann Gilbert R, Battegay Manuel, Hirschel Bernard, Bernasconi Enos, Vernazza Pietro, Giulieri Stefano, Furrer Hansjakob, Weber Rainer, Elzi Luigia, Swiss HIV Cohort Study
Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study
Fehr J, Hirschel B, Vernazza P, Martinetti G, Bernasconi E, Günthard H, Battegay M, Bucher H, Klimkait T, Fux C, Cavassini M, Glass T, Louvel S, Hamy F, Hirsch H, von Wyl V, Böni J, Yerly S, Bürgisser P, Hiv Cohort Study A. Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study. J Transl Med 2011; 9:14.
21.01.2011Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study
21.01.2011J Transl Med 2011; 9:14
Fehr Jan, Hirschel Bernard, Vernazza Pietro, Martinetti Gladys, Bernasconi Enos, Günthard Huldrych F, Battegay Manuel, Bucher Heiner C, Klimkait Thomas, Fux Christoph A, Cavassini Matthias, Glass Tracy R, Louvel Severine, Hamy Francois, Hirsch Hans H, von Wyl Viktor, Böni Jürg, Yerly Sabine, Bürgisser Philippe, Hiv Cohort Study And The Swiss